MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM.

MK-8141 (ACT-077825) is a novel potent, selective, direct Renin inhibitor for the treatment of cardiovascular disorders..

MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.

MK-8245 trifluoroacetate is a potent, selective liver-targeted stearoyl-CoA desaturase (SCD) inhibitor with IC50 of 3, 3 and 1 nM for rat, mouse and human SCD1 enzyme, respectively.

MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM.

MK-8282 is a potent, selective, oral GPR119 agonist with EC50 of 10 and 58 nM for hGPR119 and mGPR119, respectively.

MK-8318 (MK8318) is a potent, selective, orally available CRTh2 receptor antagonist with Ki of 5 nM, shows nM potency in functional assay (cAMP IC50=8 nM, β-Arrestin IC50=3.5 nM.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK

MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively.

MK-8591 (Islatravir, MK8591, EFdA) is a nucleoside analog that exhibits remarkable potency against wild-type and drug-resistant HIVs, inhibits HIV-1 reverse transcriptase with multiple mechanisms.

MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase.

MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.

MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.

MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).

MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.

MK-8998 is a novel bioactive compound for the treament of psychiatric disease.

MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM, 18F MK-9470 has been developed for use in human brain imaging..

MKC3946 is a potent and soluble IRE1α inhibitor, used for cancer research.

MKC9989 is a specific small molecule inhibitor of IRE1α Rnase (Kd=0.84 uM) with potency against the splicing of XBP1 mRNA (EC50=0.33 uM)..

MKK7-COV-13 (MKK7 Covalen inhibitor 13) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 10 nM, displays >1,000-fold selectivity over MKK4 (IC50>10 uM).

MKK7-COV-3 (MKK7 Covalen inhibitor 3) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 5 nM, displays >1,000-fold selectivity over MKK4 (IC50=7.81 uM), shows EC50 of 1.3 uM for reduction of p-JNK in ICW assays in Beas2B cell line, wit

MKK7-COV-9 (MKK7 Covalen inhibitor 9) is a potent, selective, covalent MKK7 inhibitor, displays >1,000-fold selectivity over MKK4.

MKT-077 (FJ-776) is a highly water-soluble (>200 mg/ml) rhodacyanine dye that exhibits significant antitumor activity, binds to Hsp70 family member, mortalin (mot-2), and abrogates its interactions with p53.

ML 086 is a potent, specific inhibitor of phosphatase PHOSPHO1 with IC50 of 139 nM, with no activity against TNAP (IC50>100 uM).

ML 204 isa blocker of TRPC4 channels (IC50 values are 0.96 and 2.6 μM in fluorescent and electrophysiological assays, respectively).

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 348(ML348) is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).

ML 604086 (ML604086) is a potent, selective CCR8 inhibitor that inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations with IC50 of 1.3 uM and 1.0 uM respectively in cellular assays.

ML 604440 (ML604440, ML-604440) is a potent, specific and cell permeable proteasome β1i (LMP2) subunit inhibitor.

ML 792 is a potent, seletive SUMO-activating enzyme (SAE) inhibitor with IC50 of 3 nM and 11 nM for SAE/SUMO1 and SAE/SUMO2, respectively.

ML RR-S2 CDA ammonium salt is a synthetic cyclic dinucleotide derivative that functions as a highly potent agonist of STING, enhances binding affinity to STING and activates all known human STING alleles.

ML RR-S2 CDA is a synthetic cyclic dinucleotide (CDN) that contains non-canonical 2'5'-phosphodiester bonds and is an activator of stimulator of interferon genes (STING).

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML090 (ML-090, CCG-44699, Fluoflavin, NSC 179821) is a potent, selecitve inhibitor of NADPH oxidase 1 (NOX1) with IC50 of 90 nM, displays no significant activities against NOX2, 3 and 4 (IC50>10 uM)..

ML092 is a covalent and reversible Cruzain inhibitor, with an IC50 of 10 nM.

ML-098 is an activator of the GTP-binding protein Rab7 (EC50 = 77.6 nM) that demonstrates selectivity against the related GTPases cdc42, Ras, Rab-2A, and Rac1 (EC50s = 588.8, 346.7, 158.5, and 794.3 nM, respectively).

ML104 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC50 of 40 nM.

ML115 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML119 (CID1357397.

ML-130 is a potent and selective inhibitor of NOD1; displays 36-fold selectivity for NOD1 over NOD2 (IC50 values are 0.56 and >20 μM for NOD1 and NOD2 respectively).

ML132 (NCGC-00183434, CID-4462093) is a highly potent, selective Caspase 1 inhibitor with IC50 of 0.023 nM, displays >1,000-fold selectivity over a panel of 9 caspases..

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.

ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.

ML18 is Bombesin receptor subtype 3 (BRS-3) antagonist (IC50 = 4.8 μM). ML-18 inhibits lung cancer growth.

ML-184 (ML184) is a potent, selective GPR55 agonist with EC50 of 263 nM, >120-fold, 83-fold, and 57-fold selectivity against GPR35, CB1 and CB2.

ML-191 is a potent, selective GPR55 antagonist with 160 nM potency for GPR55 and >100-fold selectivity against GPR35, CB1 and CB2.

ML193 (CID 1261822) is a potent, selective GPR55 antagonist with IC50 of 221 nM, shows >27-, >145- and >145-fold selectivity for GPR55 over CB1, GPR35 and CB2, respectively.

ML197 is a potent, selective small molecule inhibitor of Cdc2-like kinases (CLK) and DYRK with IC50 of 96/40/206 nM for CLK1/CLK4/Dyrk1A, respectively.

ML-213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener (EC50 values are 230 and 510 nM for KV7.2 and KV7.4 respectively).

ML216(CID-49852229) is a potent inhibitor of the DNA unwinding activity of BLM helicase; showing similar IC50s of 3.0 and 0.97 μM for full length BLM and BLM636–1298 respectively.

ML221 is an antagonist of the apelin (APJ) receptor.

ML-224 (ANTAG3) is a selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice.

ML-228 is a hIF pathway activator (EC50 values are 1.23 and 1.4 μM for HRE gene reporter assay and HIF-1α nuclear translocation assay respectively); acts via chelation of iron, independently of PHD.

ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).

ML-240 is am ATP-competitive inhibitor of p97 ATPase (IC50 = 110 nM).

ML241 is a potent, selective, and reversible inhibitor of the AAA ATPase p97 (IC50=100 nM). It blocks p97-dependent proteasome substrate with an IC50 of 3500 nM.

ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5).

ML-265 activates tumor-specific PKM2 (EC50 = 92 nM) by binding to the dimer-dimer interface between two subunits of PKM2 and inducing tetramerization.

ML-277 is a potent activator of KCNQ1 ( K(v)7.1) channels (EC50 = 260 nM).

ML278 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 6 nM.

ML279 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 17 nM.

ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM. ML281 showed a 550-fold selectivity over AurB and greater than 700-fold selectivity over PKA.

ML-290 is a potent and orally active relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.

ML297 (VU0456810) is the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice.

ML298 is a potent, selective phospholipase PLD2 inhibitor with IC50 of 355 nM, displays >53-fold selectivity over PLD1 (IC50>20 uM).

ML299 is a potent, CNS penetrant, dual phospholipase PLD1/PLD2 probe with IC50 of 6 nM/20 nM, respectively.

ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.

ML316 is a specific antifungal agent that fungal-selectively inhibits the mitochondrial phosphate carrier Mir1, exhibits potent antifungal activity against the moderatelyazole-resistant C. albicans strain CaCi-2 with MIC of 0.05 ug/ml.

ML323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay and 174 nM and 820 nM in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) and monoubiquitinated PCNA (Ub-PCNA) as substrates, respectively.

ML-324 is a JMJD2 histone demethylase inhibitor (JMJD2 IC50 = 920 nM)

ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

ML329 is a small molecule inhibitor of the MITF molecular pathway.

ML335 is a selective activator of both TREK-1 and TREK-2.

ML346 is a novel activator of Hsp70 with EC50 of 4600 nM in HeLa cell toxicity assay.

ML347 is a selective BMP receptor inhibitor with IC50 of 32 nM for ALK2, >300-fold selectivity over ALK3. Also inhibits ALK1 activity with IC50 of 46 nM

ML350 (CYM 50202) is a highly potent and selective Opioid kappa receptor (OPRK1/KOR) antagonist with IC50 of 9-16 nM.

ML352 (VU-0476201) is a potent, selective choline transporter (CHT) inhibitor with Ki of 92 nM.

ML354 (VU0099704) is a novel potent and selective PAR4 antagonist with IC50 of 140 nM, displays 71-fold selectivity versus PAR-1.

ML355 is a potent and selective inhibitors of 12-Lipoxygenase(12-LOX) with IC50 of 0.34 μM, excellent selectivity over related lipoxygenases and cyclooxygenases, and possess favorable ADME properties.

ML358 is a first in class, selective small molecule inhibitor of the SKN-1 pathway with IC50 of 0.24 uM.

ML359 is a small molecule, specific inhibitor of Protein disulfide isomerase (PDI) with IC50 of 250 nM; displays >100-fold selectivity over other thiol isomerases (Erp5, Thioredoxin, Thioredoxin reductase); shows no cytotoxicity in three human cell lines, and some activity in inhibiting platelet aggregation in vitro.

ML364 is an USP2 inhibitor.xtracted from patent WO 2016134026 A1, compound example 10G.

ML365 is a novel selective small molecule inhibitor of TASK1(KCNK3) with IC50 of 4 nM(thallium influx fluorescent assay) and 16 nM(automated electrophysiology assay).

ML368 (SR 9186) is a potent, selective cytochrome P450 enzyme CYP3A4 inhibitor with IC50 of 4 nM (convert testosterone to hydroxytestosterone), displays >2,000-fold selectivity over CYP3A5..

ML372 is a small molecule SMN modulator that increases SMN protein in patient fibroblasts with EC50 of 37 nM; possesses good potency, pharmacokinetics, tolerance, and CNS penetration that are able to increase levels of SMN protein in several model cell lines; increase SMN protein levels in vivo, restore motor function, and prolong survival of SMNΔ7 SMA Mice; improves the righting reflex and extended survival of a severe mouse model of SMA.

ML375 (VU-0483253) is a potent, highly selective M5 NAM with submicromolar potency (human M5 IC50=300 nM, rat M5 IC50=790 nM, M1-M4 IC50> 30 uM), exhibts excellent multispecies PK, high CNS penetration, and enantiospecific inhibition..

ML377 (MLS 0472732) is a small molecule probe that selectively inhibits TAG (Triacylglyceride) accumulation with an IC50 of 1.1 uM, show >45-fold selectivity versus DGAT inhibition and cytotoxicity..

ML378 (CID71710938, JJH-254) is an in vivo active carbamate-based dual inhibitor of lysophospholipase LYPLA1 (APT1) and LYPLA2 (APT2) with IC50 of 122 nM and 245 nM, repectively.

ML379 (CID71576758) is a potent, selective TP53 mutant cancer cells inhibitor with IC50 of 13 nM in sensitive HeLa cells (TP53 mutant).

ML381 (VU0488130) is a highly mAChR subtype selective M5 orthosteric antagonist with IC50/Ki of 450/340 nM for hM5, has no inhibitory activity on hM1-4 (IC50>30 uM).

ML382 is a potent, selective, positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MrgprX1) with EC50 of 190 nM in cell based Ca2+ imaging assay.

ML385 is a novel and specific NRF2 inhibitor.

ML387 (CID3474778) is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 19 nM.

ML388 is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 34 nM.

ML389 is a highly potent, selective vasopressin receptor 1a (V1a-R) antagonist with IC50 of 40 nM.

ML395 is a potent, selective, allosteric phospholipase D2 (PLD2) inhibitor with cellular IC50 of 360 nM, shows >80-fold selectivity over PLD1 (IC50>30 uM).

ML398 (CID72737723) is a potent, selective, highly brain penetrant dopamine 4 (D4) receptor antagonist with IC50/Ki of 130 nM/60 nM.

ML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM.

ML401 (CID73169083) is a potent, functional antagonist of EBI-2 (Epstein-Barr virus-induced gene 2) with IC50 of 1 nM, displays activity in a chemotaxis assay (IC50=6 nM).

ML402 is a selective TREK-1 activator.

ML404 is a small molecule inhibitor of mtPTP, inhibits mitochondrial swelling with EC50 of 4.9 nM, shows no effect on mitochondrial coupling at >100 uM.

ML406 is a small molecule Mtb bioA (DAPA synthase) enzyme inhibitor (IC50=30 nM) that shows anti-tubercular activity, dispalys >100-fold selectivity over bioD.

ML-60218 (ML60218) is a broad-spectrum, small molecule inhibitor of RNA polymerase (Pol) III with IC50 of 32 and 27 uM for Saccharomyces cerevisiae and human, respectively.

ML-7 Hydrochloride is a selective inhibitor of myosin light chain kinase (MLCK) (Ki = 0.3 μM).

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.

MLAF50 is the first small-molecule inhibitor of the REV1 UBM2-Ubiquitin interaction, directly binds to REV1 UBM2 with Kd of 37 uM in SPR assays.

MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC50 of 0.76 nM.

MLN 2480(BIIB-024) is an oral, selective pan-Raf kinase inhibitor in chinical trials.

MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5.

MLN0905 is a mall-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.

MLN120B is a potent and effective IKKbeta inhibitor.

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.

MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization).

MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).

MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme (NAE) with IC50 of 4 nM.

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B.

MLN8237 (Alisertib) is a selective Aurora A inhibitor with IC50 of 1.2 nM.

MLN-9708 is a proteasome inhibitor, which inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome.

MLR-1023 is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals.

MLS 0038949 is a potent, selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 0.19 uM, shows no activity against IAP and PLAP (IC50>100 uM).

MLS 0263839 is a potent, specific inhibitor of the phosphatase PHOSPHO1 with IC50 of 0.14 uM, shows minimal cross-inhibition of TNAP and no inhibition of ENPP1 activity.

MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.

MLS-0437605 is a specific inhibitor of dual-specificity phosphatase 3 (DUSP3) with IC50 of 3.7 uM, 7-fold selectivity over USP22 and >4-fold selectivity over other 10 PTPs (HePTP, TCPTP, PTP1B, etc.).

MLS1082 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).

MLS6585 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLT-747 (MLT747) is a potent, selective, allosteric inhibitor of MALT1 paracaspase with IC50 of 14 nM.

MLT-748 (MLT748) is a potent, selective, allosteric inhibitor of MALT1 paracaspase with IC50 of 5 nM, does not show inhibitory activity against 22 other tested human proteases (IC50>100 uM).

MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.

MM-102 is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM.

MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes.

MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM.

MMAE-(PEG)4-DBCO is made by MMAE conjugated to DBCO-(PEG)4 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.

MMK7 inhibitor 4a is a potent, sepecific, covalent inhibitor of MMK7, displays >800-fold selectivity over EGFR-WT and EGFR-L858R/T790M.

MMP13-IN-24f is a potent, selective, and orally active MMP-13 inhibitor with IC50/Ki of 0.5/0.19 nM, shows no activity against MMP-1 or TACE (IC50>10 uM).

MMP13-IN-31f is a highly potent, selective, orally bioavailable MMP-13 inhibitor with IC50 of 0.036 nM.

MMP-2/MMP-9 inhibitor II is a dual inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC50s = 17 and 30 nM, respectively).

MMP-2/MMP-9 inhibitor III is a cyclic peptide inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC50s = 10-20 μM for both).

MMP3 inhibitor 1 is a potent and highly selective MMP-3 inhibitor with an IC50 of 1 nM.

MMP-3 inhibitor is a peptide inhibitor of matrix metalloproteinase-3 (MMP-3) with a Ki value of 95 nM.

MMPI-1154 is a small molecule MMP-2 inhibitor with IC50 of 10/6.6/13/1.8 uM for MMP1/2/9/13, respectively.

MMRi6 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells..

MMRi64 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells.

MMSET-IN-1 is a potent, selective epigenetic oncogene MMSET (aka NSD2 or WHSC1) inhibitor with Ki/IC50 of 1.6/3.3 uM.

MMV390048 is a novel potent Plasmodium PI4K inhibitor with IC50 of 28 nM against intraerythrocytic life cycle stages of P. falciparum (NF54 drug-sensitive strain).

MMV-667492 (MMV 667492, MMV667492) is a novel potent Ezrin inhibitor with Kd of 29.4 nM.

MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression

MN30 (Methyl-3,4-dephostatin, APOBEC3G inhibitor MN30) is a first-in-class, selectve small molecule inhibitor of the single-strand DNA cytosine deaminase APOBEC3G with IC50 of 9.1 uM.

MN58b is a potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.4 uM, >30-fold selectivity over ChoKβ and does not affect MAPKs, PI3Ks, and other enzymes involved in the regulation of phospholipid metabolism.

MN-64 is a inhibitor of tankyrases, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.

MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).

MNKI-19 is a potent and dual-specific Mnk inhibitor with Ki of 186 nM and 68 nM for Mnk1 and Mnk2, respectively.

MNKI-85 is a potent and selective Mnk2 inhibitor with Ki of 31 nM, displays no inhibitory activities against Mnk1, CDK2A, CDK9T, and CDK4D.

MNKI-8e (MNK inhibitor 8e) is a potent, selective MNK inhibitor that inhibits Mnk2 with Ki of 0.37 uM, displays >34-fold and 4-fold over CDK2 (Ki>10 uM) and CDK9 (Ki=1.66 uM).

MNK-IN-54 is a potent, orally bioavailable dual MNK1/2 and BCR-ABL1 inhibitor with IC50 of 20/10/200/10 nM for Abl T315I/ wt Abl/MNK1/MNK2, respectively.

Moexipril HCl is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.

Mofezolac is a Highly Selective Cyclooxygenase-1 Inhibitors,Counteracting Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation.

Moguisteine is a novel peripheral non-narcotic antitussive drug.

Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.

Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway.

Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

Mometasone furoate

Monastrol is a reversible, cell-permeable inhibitor of the motor protein Eg5 (kinesin family protein 11, Kif11), blocking basal ATPase activity in vitro (IC50 = 6.1 µM) and inducing the formation of monoastral spindles in cell-based assays (IC50 = 51.3 μM

Monobenzone (Benoquin)

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Monomethylauristatin F(MMAF) is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin; lower cytotoxic activity than MMAE; antibody drug cytotoxin.

Monooctyl succinate is a monoester, which can be used as a surfactants and a potential fragrance releaser.

Montelukast belongs to a group of medications known as leukotriene receptor antagonists.

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Mosedipimod (EC-18, 1-palmitoyl-2-linoleoyl-3-acetylglycerol) is a synthetic monoacetyldiaglyceride that stimulates T cell production of IL-2, IL-4, IL-12, IFN-γ, and GM-CSF in vitro.

Motesanib (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret.

Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.

Motolimod (VTX-2337) is a novel TLR8 agonist that activates NK cells and augments ADCC.

Moxifloxacin(Avelox, Avalox) is a fourth generation synthetic fluoroquinolone antibacterial agent.

Moxonidine

Moxonidine hydrochloride

Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM.

MP-A08 is a first-in-class, highly selective, ATP competitive sphingosine kinase (SphK) inhibitor (Ki of 6.9/27 uM for SK2/SK1).

MPC-0767 (MPC0767, MPC3100 mesylate hydrate) is an L-alanine ester prodrug of MPC-3100, which is a potent, selective, orally bioavailable Hsp90 inhibitor with IC50 of 0.14 uM.

MPC1304 is a Ca2+ channel antagonist with potent and long-lasting antihypertensive effects. IC50 & Target: Ca2+ Channel.

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.

MPEP is a potent, highly selective non-competitive antagonist at the mGlu5a receptor subtype (IC50 = 36 nM) while having no agonist or antagonist activities at the mGlu1b receptor at concentrations up to 30 μM.

MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM.

mPGES1-IN-16 is a potent and selective mPGES-1 inhibitor with IC50 of 1 nM.

mPGES1-IN-17d is a potent, selective mPGES-1 inhibitor with enzyme IC50 of 8 nM, A549 cell IC50 of 16.24 nM, human whole blood IC50 of 249.9 nM.

MP-HJ-1b is a novel potent inhibitor of microtubule and tumor cell growth, binds the colchicine pocket at the intra-dimer interface, depolymerizes microtubules and affects spindle formation.

MPI_5a is a potent selective inhibitor of HDAC6, and poorly blocks other HDAC enzymes.

MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases.

Mps1-IN-2 is a potent Mps1 kianse inhibitor with IC50 value of 145 nM.

Mps1-IN-3 is a selective and highly potent Mps1 kinase inhibitor with IC50 of 50 nM.

MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA.

MPT0G211 is a novel potent, selective HDAC6 inhibitor with IC50 of 0.291 nM, displays >1,000-fold selectivity over other HDAC isoforms.